177lu-psma-617

177lu-psma-617 has been studied in 1 paper since 2026: 1 trial in people; 1 in the past year. The newest paper, Feb 6, 2026: “Clonal Hematopoiesis after 177Lu-PSMA-617 Radioligand Therapy in Prostate Cancer”.

Intervention

1 paper studies it4 findingsUpdated

PubChem

See all 1 papers on 177lu-psma-617

At a glance

The findings reach people, from one lab or study. 1 lab in 1 country; 6 trials, none about aging.

“increases in maximal CH VAF correlated with the number of 177Lu-PSMA-617 cycles received (+2.9% per cycle; P = 0.002).”
Clonal Hematopoiesis after 177Lu-PSMA-617 Radioligand Therapy in Prostate CancerClinical cancer research : an official journal of the American Association for Cancer Research2026doi:10.1158/1078-0432.ccr-25-4001

None of its findings points the other way.

Humans: a single group. Cells, worms or flies and mice: nothing yet.
  • 1 lab in 1 country
  • 6 trials, none about aging
  • Funders: BC Cancer Foundation and 7 more
  • 3 of 6 trials sponsored by its developers
  • Human trial1

Studies in people

1 study gave 177lu-psma-617 to people and measured what changed.

What changedDesignPeopleSource

up: Increases clonal hematopoiesis of indeterminate potential62% vs. 40%, OR 3.2, P = 0.03

up: Increases clonal expansion70.9% vs. 29.5%, P = 7.5 × 10-5

up: Increases variant allele frequency+2.9% per cycle, P = 0.002

Randomized trial107 peopleMenMCRPCClinical cancer research : an official journal of the American Association for Cancer Research, Feb 6, 2026

What did studies of 177lu-psma-617 find?

4

Studies of 177lu-psma-617 measured 4 outcomes, among them variant allele frequency, clonal expansion and PPM1D.

Variant allele frequency

upin humans1

1 study
  1. 177lu-psma-617 increases variant allele frequency in humans (mCRPC) (+2.9% per cycle, P = 0.002).

    “increases in maximal CH VAF correlated with the number of 177Lu-PSMA-617 cycles received (+2.9% per cycle; P = 0.002).”

    Human trialmCRPC

    Clonal Hematopoiesis after 177Lu-PSMA-617 Radioligand Therapy in Prostate Cancer

    Clinical cancer research : an official journal of the American Association for Cancer Research

More on Variant allele frequency

Clonal expansion

upin humans1

1 study
  1. 177lu-psma-617 increases clonal expansion in humans (mCRPC) (70.9% vs. 29.5%, P = 7.5 × 10-5).

    “CH clones expanded more frequently and to a greater magnitude with 177Lu-PSMA-617 (proportion expanding, 70.9% vs. 29.5%; P = 7.5 × 10-5)”

    Human trialmCRPCn = 107

    Clonal Hematopoiesis after 177Lu-PSMA-617 Radioligand Therapy in Prostate Cancer

    Clinical cancer research : an official journal of the American Association for Cancer Research

PPM1D

upin humans1OR 5.4

1 study
  1. 177lu-psma-617 increases PPM1D in humans (mCRPC) (OR 5.4).

    “The DNA damage response gene PPM1D accounted for 42% (51/121) of 177Lu-PSMA-617-emergent mutations, with odds ratios of 3.2 for any treatment-emergent CH and 5.4 for PPM1D, relative to cabazitaxel.”

    Human trialmCRPCn = 107

    Clonal Hematopoiesis after 177Lu-PSMA-617 Radioligand Therapy in Prostate Cancer

    Clinical cancer research : an official journal of the American Association for Cancer Research

More on PPM1D

Clonal hematopoiesis of indeterminate potential

upin humans1OR 3.2

1 study
  1. 177lu-psma-617 increases clonal hematopoiesis of indeterminate potential in humans (mCRPC) (62% vs. 40%, OR 3.2, P = 0.03).

    “Treatment-emergent CH occurred more often after 177Lu-PSMA-617 than cabazitaxel [62% (37/60) vs. 40% (19/47); P = 0.03]”

    Human trialmCRPCn = 107

    Clonal Hematopoiesis after 177Lu-PSMA-617 Radioligand Therapy in Prostate Cancer

    Clinical cancer research : an official journal of the American Association for Cancer Research

More on Clonal hematopoiesis of indeterminate potential

Who is developing 177lu-psma-617?

1 company: Novartis Pharmaceuticals.

Companies
  • Novartis PharmaceuticalsPhase 3prostatic neoplasm, metastatic castration-resistant prostate cancer

Trial sponsors

Latest

Dec 2025: 0Jan 2026: 0Feb 2026: 1Mar 2026: 0Apr 2026: 0May 2026: 0Jun 2026: 0Jul 2026: 0Aug 2026: 0Sep 2026: 0Oct 2026: 0Nov 2026: 01 paper in 12 months